¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06
±³À°ÀÏÀÚ : 2022-11-06
±³À°Àå¼Ò : ÄÚ¿¢½º ³²ÂÊ4Ãþ ÄÁÆÛ·±½º·ë  
±³À°ÁÖÁ¦ : (¿ÀÇÁ¶óÀÎ) ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÁöÀºÁ¤
¿¬¶ôó : 02-512-5915  
À̸ÞÀÏ : gyncancer@gyncancer.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í Àü¹®ÀÇ 5¸¸¿ø, Àü°øÀÇ3¸¸¿ø, ¿¬±¸¿ø/°£È£»ç2¸¸¿ø, ÁÂÀå/¿¬ÀÚ/Åä·ÐÀÚ/¸¸65¼¼ÀÌ»ó ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-06 401È£ 09:00~09:10 ºÎÀÎÁ¾¾çÀÇÇлó, JGO Best Reviewer ½Ã»ó½Ä  () 
±âŸ 11-06 401È£ 09:10~09:15 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ¹ßÇ¥  () 
±âŸ 11-06 401È£ 09:15~09:20 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ»ó ¼ö»óÀÚ ¹ßÇ¥  () 
±³À°½Ã°£ 11-06 401È£ 09:20~09:35 Ovarian cancer  ³²¼ÒÇö(¿ï»êÀÇ´ë) 
Åä·Ð 11-06 401È£ 09:35~09:40 Designated discussion  ÀÌÀºÁö(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 09:40~09:55 Cervical cancer and uterine cancer  ³ëÁØÈ£(¼º±Õ°üÀÇ´ë) 
Åä·Ð 11-06 401È£ 09:55~10:00 Designated discussion  Àü¼·(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:00~10:15 Risk classification of endometrial cancer  ¹Ú¼öÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:15~10:30 BRCA and HRD in high-grade ovarian cancer  ³²ÀºÁö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:30~10:45 PD-L1, TMB, MMR status, and beyond for immunotherapy  ÃÖÀ±Áø(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 401È£ 10:45~11:00 Designated discussion  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
È޽Ġ11-06 401È£ 11:00~11:20 Coffee Break  () 
±³À°½Ã°£ 11-06 401È£ 11:20~11:35 Will the importance of complete cytoreduction continue or shrink?  ±èÅÂÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 11:35~11:50 HIPEC or not, that is the question  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 11-06 401È£ 11:50~12:05 Are you ready for relapse after PARP inhibitors?  ¹ÚÁ¤¿­(¿ï»êÀÇ´ë) 
Åä·Ð 11-06 401È£ 12:05~12:20 Designated discussion  Á¤´ëÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 12:20~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 12:35~12:50 Long-term results of PARPi as maintenance in front-line  Antonio González Martín(Clínica Universidad de Navarra) 
½Ä»ç 11-06 401È£ 12:50~13:40 Lunch  () 
±³À°½Ã°£ 11-06 401È£ 13:40~13:55 Less radical surgery in early-stage cervical cancer  ¹èÀ縸(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 13:55~14:10 Quality indicators of the radical surgery  °øÅ¿í(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:10~14:25 CCRT: current standard & future perspective  ±è¿ë¹è(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) 
Åä·Ð 11-06 401È£ 14:25~14:40 Designated discussion  ³ëÁÖ¿ø(Â÷ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:40~14:55 Fertility-preservation in gynecologic cancers  ÀÌ»óÈÆ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:55~15:10 How to optimize elderly patients for cancer treatments?  ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 15:10~15:25 Management of immunotherapy and targeted therapies-induced toxicities  ÀåűÔ(°è¸íÀÇ´ë) 
Åä·Ð 11-06 401È£ 15:25~15:40 Designated discussion  ¹Ú¼ºÈ£(ÇѸ²ÀÇ´ë) 
È޽Ġ11-06 401È£ 15:40~16:00 Coffee Break  () 
±³À°½Ã°£ 11-06 401È£ 16:00~16:15 Uterine sarcoma  ¼Ò°æ¾Æ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 16:15~16:30 Ovarian clear cell cancer  ¼­µ¿¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 16:30~16:45 Ovarian low grade serous cancer  È«´ë±â(°æºÏÀÇ´ë) 
Åä·Ð 11-06 401È£ 16:45~17:00 Designated discussion  ±Çº´¼ö(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 13:40~13:55 Assessment of quality of cancer patients  Á¶ÁÖÈñ(¼º±Õ°ü´ë À¶ÇÕÀÇ°úÇпø) 
±³À°½Ã°£ 11-06 403È£ 13:55~14:10 Tailored surgery for cervical cancer  ±¸À¯Áø(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 14:10~14:25 Guidelines and issues for ovarian cancer treatment  ±è»óÀÏ(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 403È£ 14:25~14:35 Discussion  () 
±³À°½Ã°£ 11-06 403È£ 14:35~14:50 ERAS & perioperative management  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 14:50~15:05 Issue of nursing problem during the acute survival period  ±èÁÖÇö(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 11-06 403È£ 15:05~15:20 Clinical trial and research ethics related to gynecologic oncology  ±è¼ö(¿¬¼¼´ë °£È£´ëÇÐ) 
Åä·Ð 11-06 403È£ 15:20~15:30 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºÐ´ç¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ)¾È°úÁúȯÀÇ ÃÖ½ÅÁö°ß(½Ç¸í±Ùó¿¡ ´Ù´Ù¸¥ ³ì³»Àå) : 2022-11-08
´ÙÀ½±Û 2022³â Á¦21Â÷ ¾Æ½Ã¾ÆÇÙÀÇÇÐÇù·Â±â±¸ Çмú´ëȸ ¹× Á¦61Â÷ ´ëÇÑÇÙÀÇÇÐȸ Ãß°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-11-05
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20973 °­¿ø 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Á¦21Â÷ ¿öÅ©¼ó : 2024-06-21 0 4 2024-06-14
20972 ¼­¿ï Á¦23ȸ Çѱ¹Á¤¸Æ°æÀ念¾çÇÐȸ Çмú´ëȸ ¹× 2024 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-21 0 4 2024-06-14
20971 ¼­¿ï ´ëÇѼҾƳ»ºÐºñÇÐȸ 2024³â Á¦1Â÷ Á¤±âÁý´ãȸ(°íÇÁ·Î¶ôƾÇ÷Áõ) : 2024-06-21 0 2 2024-06-14
20970 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 2Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-21 0 2 2024-06-14
20969 °æ±â ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Annual Academy for young oncologists(1ÀÏÂ÷) : 2024-06-21 0 2 2024-06-14
20968 °æºÏ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦43Â÷ ÇÏ°è±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-21 0 0 2024-06-14
20967 Á¦ÁÖ Á¦ÁÖÇѶ󺴿ø º¹°­°æ ½ÉÆ÷Áö¿ò : 2024-06-21 0 1 2024-06-14
20966 °æ±â ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ 2024³âµµ Á¦27Â÷ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-21 0 1 2024-06-14
20965 Á¦ÁÖ ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ The 18th Annual Summer Conference on Endovascular Neurosurgical Therapy (ASCENT 2024) 1ÀÏÂ÷ : 2024-06-21 0 1 2024-06-14
20964 ¼­¿ï 2024³â ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-20 0 3 2024-06-14
20963 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1ȸ ¼­¿ïÀÇ·á¿ø Áö¿ª»çȸ ¿¬¼ö°­Á : 2024-06-20 0 2 2024-06-14
20962 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1ȸ ¼­¿ïÀÇ·á¿ø Áö¿ª»çȸ ¿¬¼ö°­Á : 2024-06-20 0 2 2024-06-14
20961 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 2Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-20 0 1 2024-06-14
20960 ºÎ»ê ´ëÇѺ´¸®ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ 6¿ù ¿¬¼ö±³À° : 2024-06-20 0 0 2024-06-14
20959 ¼­¿ï (¿Â¶óÀÎ) 2024 ÀÀ±Þ½ÉÀ忬±¸È¸ ½ÉÀüµµ ½ÉÆ÷Áö¿ò : 2024-06-20 0 0 2024-06-14
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷